The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

Pamela Stephenson net worth and biography

Pamela Stephenson Biography and Net Worth

insider of Albireo Pharma

Pamela Stephenson joined Albireo in March 2019 as Chief Commercial Officer. Pamela has more than 20 years of biopharma commercial leadership experience across multiple functions and disease areas. Before joining Albireo, she served as Vice President, Global Market Access and Value, at Vertex Pharmaceuticals, where she led the global market access and pricing strategy for current and future products. Earlier in her tenure at Vertex, she led marketing and sales activities for the company’s hepatitis C and cystic fibrosis lines of business, and oversaw the U.S. launches of Incivek® (telaprevir) and Orkambi®(lumacaftor/ivacaftor). Prior to Vertex, Pamela spent 10 years at Pfizer in marketing roles of increasing responsibility for brands such as Viagra® (sildenafil citrate), Lyrica® (pregabalin), and Aromasin® (exemestane). She holds a bachelor’s degree from Brown University and received her master’s degree in public health from Boston University School of Public Health.

What is Pamela Stephenson's net worth?: The estimated net worth of Pamela Stephenson is at least $3.35 million as of June 14th, 2023. Ms. Stephenson owns 75,778 shares of Albireo Pharma stock worth more than $3,345,599 as of April 20th. This net worth approximation does not reflect any other assets that Ms. Stephenson may own. Learn More about Pamela Stephenson's net worth.
How do I contact Pamela Stephenson?: The corporate mailing address for Ms. Stephenson and other Albireo Pharma executives is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. Albireo Pharma can also be reached via phone at (857) 254-5555 and via email at [email protected]. Learn More on Pamela Stephenson's contact information.
Has Pamela Stephenson been buying or selling shares of Albireo Pharma?: Pamela Stephenson has not been actively trading shares of Albireo Pharma over the course of the past ninety days. Most recently, Pamela Stephenson sold 102 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $43.80, for a transaction totalling $4,467.60. Following the completion of the sale, the insider now directly owns 42,755 shares of the company's stock, valued at $1,872,669. Learn More on Pamela Stephenson's trading history.
Who are Albireo Pharma's active insiders?: Albireo Pharma's insider roster includes Ronald Cooper (CEO), Jason Duncan (Insider), Simon Harford (CFO), Patrick Horn (Insider), Jan Mattsson (Insider), and Pamela Stephenson (insider). Learn More on Albireo Pharma's active insiders.

Pamela Stephenson Insider Trading History at Albireo Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/23/2023	Sell	102	$43.80	$4,467.60	42,755
12/27/2022	Sell	469	$19.06	$8,939.14	45,178
10/24/2022	Sell	104	$19.58	$2,036.32	45,647
9/26/2022	Sell	445	$19.40	$8,633.00	45,751
6/27/2022	Sell	461	$19.47	$8,975.67	45,755
3/28/2022	Sell	454	$30.52	$13,856.08
12/27/2021	Sell	474	$23.92	$11,338.08
9/27/2021	Sell	451	$32.05	$14,454.55
6/25/2021	Sell	471	$36.01	$16,960.71	17,117
3/29/2021	Sell	422	$34.02	$14,356.44
12/28/2020	Sell	460	$39.07	$17,972.20
9/25/2020	Sell	451	$33.20	$14,973.20
6/25/2020	Sell	397	$30.79	$12,223.63
3/25/2020	Sell	1,785	$17.60	$31,416.00

Pamela Stephenson Buying and Selling Activity at Albireo Pharma

Albireo Pharma Company Overview

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Today's Range

Now: $44.15

$43.99

$44.90

50 Day Range

MA: $44.17

$43.50

$44.95

2 Week Range

Now: $44.15

$16.02

$45.23

Volume

1,241,200 shs

Average Volume

704,539 shs

Market Capitalization

$913.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03